Skip to main content

Drug Discovery Overview For Genu recurvatum Condition and Treatment Analysis

Genu recurvatum is also known as knee hyperextension or back knee. It is a type of condition that affects the knee joint to bend backward when the person is in standing position. This problem is more common in women than in men and commonly identified in 0.5%-1.0% of patients undergoing Total knee arthroplasty (TKA).
 
Genu recurvatum can also cause other conditions such as knee pain or knee osteoarthritis. Genu recurvatum can be mild, moderate, or severe. This deformity can also arise from other medical conditions such as, quadriceps weakness, bone deformities, paralysis, plantar foot flexion, and high tibial osteotomies. Genu recurvatum can be congenital or acquired. Congenital genu recurvatum (CGR) is extremely rare condition and found to be associated with other malformations such as talipes equinovarus, hip dysplasia, and absent patella.
 
High cost of treatment & management genu recurvatum and related disorders, and lack of infrastructure in the middle- and low-income countries may hinder the growth of the market.
 
It is estimated that genu recurvatum market is expected to grow at a CAGR 4.5% during the forecast period of 2017-2023.
 
 
Rising geriatric population, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of genu recurvatum market. According to the data suggested by WHO in 2015, it is found that, worldwide, one in eight people was aged 60 years or over and by 2030, older people are projected to account for one in six people globally.
 
Genu recurvatum market  Key Players
Some of key the players in the market are –
  • DePuy Synthes Companies (Part of Johnson & Johnson Services Inc.)
  • Globus Medical Inc.
  • Medtronic plc
  • NuVasive Inc.
  • Smith & Nephew plc
  • Stryker Corporation
  • Zimmer Inc and others.
 
Genu recurvatum market Segmentation
The Genu recurvatum market is segmented on the basis of type, diagnosis, treatment, and end-user.
 
On the basis of type, market is segmented into external rotatory deformity (ERD), internal rotatory deformity (IRD), and non-rotatory deformity (NRD).
 
On the basis of diagnosis, market is segmented into magnetic resonance imaging (MRI), x-rays, and others.
 
On the basis of treatment, market is classified into physical therapy, orthoses, bracing, and surgery.
 
On the basis of end-user, market is segmented into hospital, clinics, and others.
 
Intended Audience
  • Hospitals
  • Surgical equipment Companies
  • Diagnostic clinics
  • Research and Development (R&D) Companies
  • Government Research Institute
  • Academic Institutes and Universities 
 
LIST OF TABLES
 
Table 1 Genu Recurvatum Industry Synopsis, 2017 – 2023
Table 2 Genu Recurvatum Market Estimates And Forecast, 2017 – 2023, (USD Million)
Table 3 Genu Recurvatum Market By Region, 2017 – 2023, (USD Million)
Table 4 Genu Recurvatum Market By Types, 2017 – 2023, (USD Million)
Table 5 Genu Recurvatum Market By Diagnosis, 2017 – 2023, (USD Million)
…To be Continued.
 
 
Genu recurvatum market Regional Analysis
 
The Americas dominate the Genu recurvatum market owing to the rising awareness among people and increasing healthcare expenditure. Centers for Disease Control and Prevention (CDC) has stated that out of the total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States. Furthermore, increasing participation of bigger players and new marketers towards advancement in treatment approaches have also attracted a great deal of attention.
 
Europe holds the second position in the Genu recurvatum market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in the European region.
 
Asia Pacific is the fastest growing genu recurvatum market owing to the huge patient pool and developing healthcare technology.
 
The Middle East & Africa has the lowest market for rabies treatment market due to lack of technical knowledge and poor medical facilities. 

Comments

Popular posts from this blog

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Growth Drivers, Restraints and Opportunities, Forecast To 2025

Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size Research Report: Information by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025 Global  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size  Insights 2020 provides a unique tool for evaluating the Market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. Some of the key players operating for the global market analysis are  Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova, Inc., Bristol-Myers Squibb Company, Galapagos NV, F. Hoffmann-La Roche AG, Fibro

Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Regional Analysis, Competitive Landscape Forecast to 2023

Idiopathic Pulmonary Fibrosis Treatment is a life-threatening condition of the lungs in which tissues becomes thickened, stiff, and scarred over a long period. The IPF treatment market is driven by various factors such as growing demand for minimally invasive procedures to diagnose and treat different chronic diseases, increasing geriatric population, along with the rising prevalence rates of IPF and other fibrotic diseases. Market Overview The high cost of surgery and the unavailability of proper treatment options are expected to curb the growth of the IPF treatment. The Global  Idiopathic Pulmonary Fibrosis Treatment Market  is expected to register a  CAGR of 12.3%  during the forecast period of 2019 to 2025, with a market value of USD 2,237 million in 2018. The global IPF treatment market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in Sept

Chatbots in Healthcare Market Research Report by Top Industry Vendors and Applications Scenario till 2023

Chatbots in Healthcare Market Overview Healthcare chatbots are programs which assist patients with queries. This reduces the burden on the clinical staff and lets them focus on their jobs. Automation of various workflow processes in the healthcare sector is likely to propel the demand for these virtual assistants. The global Chatbots in Healthcare Market is expected to touch USD 316.85 million by 2023 at 21.10% CAGR over the forecast period (2018-2023), as per Market Research Future (MRFR). It stood at USD 100.46 million in 2017. Rise of chronic diseases coupled with lack of medical experts to handle queries are main drivers of the market. For instance, cancer patients used chatbots to gain rapid assistance regarding medication and their adverse effects.  The  Chatbots in Healthcare Market   Free Growth Sample will provide valuable insight with an emphasis on the global market including some of the  major players  such As,  Sensely, Inc. (U.S.), Your.MD (U.K.), Buoy Healt